866-997-4948(US-Canada Toll Free)

Immune Check Activators - Competitive Landscape, Technology and Pipeline Analysis, 2016

Published By :

DelveInsight

Published Date : Jul 2016

Category :

Oncology

No. of Pages : 121 Pages

DelveInsight's report deals with the TNFR/TNF superfamily members as agents of Cancer Immunotherapy that have brought a new dawn upon the existing therapies for cancer. Controlling diverse facets of immune function, it has brought into application a technology that rested in the pipeline for years. In the present scenario, members of the TNFR/TNF superfamily are being targeted to maintain, modulate and regulate bodys own immune system to fight cancer. The rationale of this therapy is to mitigate/ avoid side effects, resistance, toxicity and pain brought by the combination therapy of surgery, radiation and chemotherapy. The future of this therapy lies strong as will be seen before 2020 as majority of its products will show results on safety, efficacy and dosing as they move to their Phase II trials in the provided timeline.

Note: This report will be delivered to the client in 48 hours

Report Highlights

Immune Checkpoint Activators Therapy Pipeline scenario
Collaborations & partnering deals
Current Prominent Research Areas and Key Players
Pipeline product profiles Immune Checkpoint Activators Technologies and Targeted Antigens
Licensing opportunities
Market Drivers and Barriers
Table of Contents

1 Executive Summary
2 Executive Summary Snapshot
3 Immune checkpoints Activator Overview
Rationale for targeting Immune checkpoint Agonist in oncology
Stimulatory checkpoint molecules
Advantages of Immune checkpoint Activators
Constraints of Immune Checkpoint Activators
Future of Immune Checkpoint Activators in Cancer Therapy
4 ImmuneCheck Activators Analysis
ImmuneCheck Activators- Market Analysis
Collaborations and Deals
Companies received Grants for Immune checkpoints Activator
Companies Investment Details for Future Development
Licensing Opportunities
5 Market Drivers
6 Market Barriers
ImmuneCheck Activators - Pipeline Analysis
Number of Products
Therapeutic Areas Targeted
Stagesof Development
Companies Involved
Technological Platform Utilized
Clinical Trials Analysis
Clinical Products and Study Completion Year
Phase II Drug: Trials Status and Completion Year
Phase I Drugs:Trials Status and Completion Year
Studies Analysisfor the Key Targets Antigens
7 Pipeline Therapeutics
Therapeutics under Development by Companies
8 Late Stage Products (Phase III)
Comparative Analysis
9 Mid Stage Products (Phase II)
Comparative Analysis
10 Early Stage Products (Phase I and IND)
Comparative Analysis
24 Pre-Clinical and Discovery Products
Comparative Analysis
44 Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Appendix
DelveInsight Consulting Services
About DelveInsight
Contact Us
Disclaimer

List of Tables

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2016
Table 3: Companies of Immune checkpoints Activators received grants, 2016
Table 4: Companies Investment Details for Immune checkpoints Activators, 2016
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2016
Table 10: Number of Products under Development by Companies, 2016
Table 11: Mid Stage Products (Phase II),2016
Table 12: Early Stage Products (Phase I and IND), 2016
Table 13:Pre-Clinical and Discovery Products, 2016
Table 14: Assessment by Monotherapy Products,2016
Table 15: Assessment by Combination Products, 2016
Table 16: Assessment by Route Of Administration, 2016
Table 17: Assessment by Stage and Route Of Administration, 2016
Table 18: Assessment by Molecule Type, 2016
Table 19:Assessment by Stage and Molecule Type, 2016

List of Figures

Figure 1: ImmuneCheck Activators -Companies and Collaborations (N) and Investment (Million)
Figure 2: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 3: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 4: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 9: ImmuneCheck Targets-Study Completion Date, Indication and Recruitment status.
Figure 10: ImmuneCheck Targets-Drugs and Study Completion Year
Figure 11: Number of Products under Development for Immune checkpoints Activator, 2016
Figure 12: Mid Stage Products (Phase II),2016
Figure 13:Early Stage Products (Phase I and IND), 2016
Figure 14:Pre-Clinical and Discovery Products,2016
Figure 15: Assessment by Monotherapy Products,2016
Figure 16: Assessment by Combination Products, 2016
Figure 17: Assessment by Route of Administration, 2016
Figure 18: Assessment by Stage and Route of Administration, 2016
Figure 19: Assessment by Molecule Type, 2016
Figure 20: Assessment by Stage and Molecule Type, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *